-
Satellos reports safety data of SAT-3247 in Duchenne muscular dystrophy trial
13 Oct 2025 17:58 GMT
… safe with a desirable pharmacokinetic profile.
Discover B2B Marketing … a safe and clinically meaningful treatment.
“We are excited … typically observed in Duchenne muscular dystrophy within this age group. … randomised proof-of-concept trial of SAT-3247 in …
-
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Hit US$6.64B by 2033, Industry Developments, Future Growth
13 Oct 2025 14:02 GMT
… Pharmaceuticals, among others.
• The Duchenne Muscular Dystrophy … while exon-skipping drugs exceed $300K … Food and Drug Administration (FDA) approval of … Duchenne Muscular Dystrophy Treatment Market
North America Duchenne Muscular Dystrophy Treatment …
-
Global Duchenne Muscular Dystrophy Therapeutics Market to hit $ 6.64 billion by 2033 with Gene Therapy innovations
13 Oct 2025 13:46 GMT
… dunche-muscular-dystrophy-therapeutics-market
The Duchenne Muscular Dystrophy ( … , exon-skipping drugs, and RNA … pharmacies and specialty pharmacies, reflecting the specialized nature of these treatments … accelerated FDA approvals, orphan drug designations, …
-
AskBio reports AB-1003 safety data for limb-girdle muscular dystrophy
13 Oct 2025 10:56 GMT
… AB-1003 for limb-girdle muscular dystrophy (LGMD) 2I/R9 … weeks following treatment as part of the main trial, prior … developing an effective treatment for limb-girdle muscular dystrophy.”
The dose- … two sequential cohorts.
This trial commenced in 2023 and …
-
AskBio presents interim safety results from phase 1/phase 2 LION─CS101 clinical trial of AB─1003 in participants with limb─girdle muscular dystrophy 2I/R9
13 Oct 2025 08:59 GMT
… participants with limb-girdle muscular dystrophy (LGMD) 2I… weeks post-treatment during the main trial before … after adjusting corticosteroid treatment.
The data presented … treatment for limb-girdle muscular dystrophy.”
The LION-CS101 clinical trial …
-
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
13 Oct 2025 13:40 GMT
… .S. Food and Drug Administration (FDA) regarding its upcoming … drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy … the FDA; preliminary results of a clinical trial are … dates in the clinical trial of del-zota, and …
-
CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
13 Oct 2025 13:40 GMT
… support clinicians in treating difficult-to-treat Gram-positive … , please contact Cumberland Pharmaceuticals Medical Affairs at MSLsupport … drug is approved in the U.S. for the treatment … in patients with Duchenne muscular dystrophy, systemic sclerosis and …
-
Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off
13 Oct 2025 05:23 GMT
… month.
As for rejected drug applications, these were trending … s cell therapy for Duchenne muscular dystrophy was rejected in July, … both BioSpace and Jefferies. Treatments for infectious diseases and … term, the FDA approved 46 new drugs—more than double …
-
STAT+: Sarepta to seek approval for gene therapy in rare form of muscular dystrophy
11 Oct 2025 00:32 GMT
… -girdle muscular dystrophy (LGMD) 2E. That would make it the first approved treatment … its other treatments, including its approved gene therapy for Duchenne muscular dystrophy, Elevidys … coverage and analysis of the pharma industry — by subscribing to STAT …
-
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
10 Oct 2025 13:54 GMT
… muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment … tolerability, and expected pharmacokinetics (PK) across all … improving medicines to treat degenerative muscle diseases, … the Phase 1b trial are now …
About
© 1995-2025